All In MedTech

Device Trial Radar · NCT07900984

A Retrospective Registry of Intelliblate DUAL Channel Microwave Ablation

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Feb 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Varian, a Siemens Healthineers CompanyNot on our public-company list
Sponsor type
Industry
First posted
Oct 28, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study reviews past patient records from multiple hospitals to learn how safe and effective the IntelliBlate Microwave Ablation System is when used to treat liver tumors with two probes at the same time.

Conditions

  • Liver Ablation
  • Liver Cancer
  • Liver Cancer (Primary and Metastatic)

Interventions

  • Intelliblate Microwave Ablation (MWA) SystemDevice

    Subjects will have undergone at least one dual channel MWA treatment in the liver using the Intellblate MWA system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30-Day Major Complication RateTime frame: Treatment to 30 days of follow-up

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.